In BC, the first ADC to gain regulatory approval was ado-trastuzumab emtansine (T-DM1) in 2013 for HER2+ disease, followed by fam-trastuzumab deruxtecan (T-DXd, DS-8201) in 2022 (104). Here, ERBB2 is linked to breast cancer.